Organon (OGN) Total Liabilities (2020 - 2026)
Organon (OGN) posted quarterly Total Liabilities of $12.2 billion for Q2 2026, down 4.66% year-over-year from $12.8 billion in Q2 2025, and up 0.65% on a QoQ basis from $12.1 billion in Q1 2026.
Organon (OGN) Total Liabilities (2020 - 2026) Analysis & Trends
Organon has reported Total Liabilities for 7 years, with the latest figure at $12.2 billion in Q2 2026.
- Total Liabilities for Q2 2026 came in at $12.2 billion, down 4.66% year-over-year; the trailing twelve-month figure through Jun 2026 was $12.2 billion (down 4.66% YoY), and the FY2025 annual result was $12.1 billion, down 4.07% from the prior year.
- Total Liabilities climbed to $12.2 billion in Q2 2026, from $12.1 billion in the prior quarter.
- Over five years, Total Liabilities peaked at $12.8 billion in Q2 2025 and troughed at $10.4 billion in Q3 2022.
- A 5-year average of $11.8 billion and a median of $12.1 billion in 2024 frame the typical range for Total Liabilities.
- The widest annual swing landed in 2022, when Total Liabilities decreased 7.92%; it then climbed 11.15% in 2023.
- A 5-year view of Total Liabilities shows it stood at $11.8 billion in 2022, then climbed by 2.37% to $12.1 billion in 2023, then gained by 4.13% to $12.6 billion in 2024, then retreated by 4.07% to $12.1 billion in 2025, then increased by 0.47% to $12.2 billion in 2026.
- Per Business Quant data, the three most recent Total Liabilities figures were $12.2 billion in Q2 2026, $12.1 billion in Q1 2026, and $12.1 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 647.98 Bn | 627.22 Bn | 17.26 Bn | 116.09 Bn |
| 2 | AbbVie | 466.45 Bn | 459.88 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 372.04 Bn | 364.90 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 299.31 Bn | 291.62 Bn | 11.24 Bn | 80.09 Bn |
| 5 | Astrazeneca | 256.25 Bn | 251.35 Bn | 12.86 Bn | 65.46 Bn |
| 6 | Amgen | 235.50 Bn | 221.52 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 179.68 Bn | 176.50 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 159.26 Bn | 147.56 Bn | 10.94 Bn | 115.64 Bn |
| 9 | Gsk | 104.79 Bn | 100.62 Bn | 8.24 Bn | -59.79 Bn |
| 10 | Organon | 3.61 Bn | 2.47 Bn | 847.00 Mn | 12.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.17 Bn |
| Mar 31, 2026 | 12.09 Bn |
| Dec 31, 2025 | 12.12 Bn |
| Sep 30, 2025 | 12.65 Bn |
| Jun 30, 2025 | 12.77 Bn |
| Mar 31, 2025 | 12.61 Bn |
| Dec 31, 2024 | 12.63 Bn |
| Sep 30, 2024 | 12.26 Bn |
| Jun 30, 2024 | 12.01 Bn |
| Mar 31, 2024 | 11.84 Bn |
| Dec 31, 2023 | 12.13 Bn |
| Sep 30, 2023 | 11.60 Bn |
| Jun 30, 2023 | 11.53 Bn |
| Mar 31, 2023 | 10.76 Bn |
| Dec 31, 2022 | 11.85 Bn |
| Sep 30, 2022 | 10.44 Bn |
| Jun 30, 2022 | 10.61 Bn |
| Mar 31, 2022 | 10.60 Bn |
| Dec 31, 2021 | 10.68 Bn |
| Sep 30, 2021 | 11.34 Bn |